Journal
TRENDS IN BIOTECHNOLOGY
Volume 36, Issue 11, Pages 1183-1198Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2018.06.010
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [31471251]
- Natural Science Foundation of Jiangsu Province [BK20161130]
- Six Talent Peaks Project in Jiangsu Province [SWYY-128]
- National Science and Technology Major project [2018ZX10302205-004-002]
- Research Funds for the Medical School of Jiangnan University ESI special cultivation project [1286010241170320]
- Postgraduate Education Reform Project of Jiangsu Province
- Australian Research Council Discovery Early Career Research Award [DE130101550]
- Australian Government
Ask authors/readers for more resources
Atmospheric pressure gas plasmas are emerging as a promising treatment in cancer that can supplement the existing set of treatment modalities and, when combined with other therapies, enhance their selectivity and efficacy against resistant cancers. With further optimisation in production and administration of plasma treatment, plasma-enabled therapy has a strong potential to mature as a tool for selectively curing highly resistant solid tumours. Although intense preclinical studies have been conducted to exploit the unique traits of plasma as an oncotherapy, few clinical studies are underway. This review identifies types of cancers and patient groups that most likely benefit from plasma oncotherapy, to introduce clinical practitioners to plasma therapy and accelerate the speed of translating plasma for cancer control in clinics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available